Company Filing History:
Years Active: 2018-2019
Title: Nuria Gavaldà Batalla: Innovator in Amyloidosis Therapy
Introduction
Nuria Gavaldà Batalla is a prominent inventor based in Barcelona, Spain. She has made significant contributions to the field of medicine, particularly in the treatment of transthyretin-associated amyloidosis. With a total of 2 patents, her work is paving the way for innovative therapies that address this complex condition.
Latest Patents
Nuria's latest patents focus on the use of catechol-O-methyltransferase (COMT) inhibitors for the prevention and treatment of transthyretin-associated amyloidosis. These patents detail the application of COMT inhibitors both as standalone treatments and in combination with other therapeutic agents, including benzoxazole derivatives, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, and epigallocatechin-3-gallate. This innovative approach aims to enhance the efficacy of treatments for patients suffering from this debilitating disease.
Career Highlights
Nuria Gavaldà Batalla is currently associated with Som Innovation Biotech, S.L., where she continues to develop groundbreaking therapies. Her dedication to research and innovation has positioned her as a key figure in the biotech industry, particularly in the realm of amyloidosis treatment.
Collaborations
Throughout her career, Nuria has collaborated with notable colleagues, including Marc Centellas Casado and Raúl Insa Boronat. These partnerships have fostered a collaborative environment that enhances the development of effective therapies.
Conclusion
Nuria Gavaldà Batalla's contributions to the field of medicine, particularly in the treatment of transthyretin-associated amyloidosis, highlight her role as an innovative inventor. Her work continues to inspire advancements in therapeutic approaches, ultimately benefiting patients in need.